Showing 6,821 - 6,840 results of 47,671 for search '"reporter"', query time: 0.13s Refine Results
  1. 6821
  2. 6822
  3. 6823
  4. 6824
  5. 6825

    Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis by Andrew Blauvelt, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, Michael Behling, Amber Reck Atwater, Hany ElMaraghy, April Armstrong

    Published 2025-12-01
    “…Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Severity Index (EASI) response categories using pooled Advocate1 and ADvocate2 data (post hoc analysis).Methods In the 52-week (W) (16-W induction + 36-W maintenance) double-blind, placebo-controlled ADvocate1 and ADvocate2 studies, patients were randomized (2:1) to receive subcutaneous lebrikizumab 250 mg or placebo every 2 weeks. …”
    Get full text
    Article
  6. 6826
  7. 6827
  8. 6828
  9. 6829
  10. 6830
  11. 6831
  12. 6832
  13. 6833
  14. 6834
  15. 6835
  16. 6836
  17. 6837
  18. 6838
  19. 6839
  20. 6840